MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.06 -3.64

Buy Sell

Overview

Share price change

24h

Current

Min

1.04

Max

1.09

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+318.02% upside

Market Stats
By TradingEconomics
Market Cap	-9.2M 117M
Previous open	4.7
Previous close	1.06

News Sentiment

By Acuity

29%

71%

87 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 sty 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8 sty 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8 sty 2026, 20:54 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- Update

8 sty 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks

8 sty 2026, 17:05 UTC

Acquisitions, Mergers, Takeovers

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8 sty 2026, 16:43 UTC

Major Market Movers

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8 sty 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 sty 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8 sty 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sty 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8 sty 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8 sty 2026, 21:53 UTC

Earnings

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 sty 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 sty 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8 sty 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8 sty 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8 sty 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8 sty 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8 sty 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8 sty 2026, 17:48 UTC

Earnings

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 sty 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sty 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8 sty 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sty 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8 sty 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8 sty 2026, 15:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Defends Its Hostile Bid for Warner -- Update

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

318.02% upside

12 Months Forecast

Average 4.64 USD 318.02%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

87 / 372 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.